Search Results
Sep 02, 2025, 02:20 ET Global Cancer Diagnostics Market to Hit USD 215 Billion by 2035, Growing at 6.35% CAGR | Vantage Market Research
between 2025 and 2035.Dna Sequencing Market is valued at USD 15.4 Billion in 2024 and is projected to reach a value of USD
More news about: Vantage Market Research
Sep 01, 2025, 10:45 ET Digital Pathology Market to Grow at a CAGR of 7.8% from 2025 to 2032 | SkyQuest Technology Consulting
https://www.skyquestt.com/report/cell-cryopreservation-market Recombinant DNA Technology Market - Global Opportunity Analysis and Industry Forecast – 2032 https://www.skyquestt.com/report/recombinant-dna-technology-market About SkyQuest
More news about: SkyQuest Technology
Sep 01, 2025, 03:20 ET Antier Rolls Out AI Modules for Crypto Exchanges
build stronger regulatory credibility. "On-chain intelligence is the next axis for exchanges to race on. At Antier, we're building AI into the DNA of exchanges so that our clients stay ahead in performance, compliance, and user trust."
More news about: Antier Solutions
Aug 30, 2025, 03:37 ET 제이씨바이오•MGI 테크, 한국 내 멀티오믹스 혁신 촉진 위한 DCS 연구소 프로젝트 협력 발표
이니셔티브는 해외 연구소에 포괄적인 시퀀싱 솔루션을 제공하기 위해 2023년 출범했다. MGI의 세 가지 핵심 기술인 DNA 유전체학(DNA genomics), 세포 오믹스(Cell omics), 공간 오믹스(Spatial omics)의 영어명 첫 글자를 따서 만든 이름 'DCS 랩 이니셔티브'는 프런티어 과학의 중심에서 해외 연구소를 지원하기 위한 회사의 첫 글로벌 프로그램이다. 이를 통해 MGI는 업계 내에서 DNA 유전체학부터 세포 오믹스와 공간 오믹스에 이르는 응용 분야에 엔드투엔드 제품을 제공할 수 있는 독보적
More news about: MGI Tech
Aug 29, 2025, 20:15 ET Foresight Diagnostics and Roche Enter Licensing Agreement for PhasED-Seq™ Technology in Non-Hodgkin's Lymphoma
concordant detection of two separate non-reference events in an individual DNA molecule. By detecting more than one mutation, PhasED-Seq can more accurately distinguish tumor-derived cell free DNA (i.e., ctDNA) from healthy cell free DNA – enabling detection of ctDNA at levels below one part-per-million (<0.0001%).
More news about: Foresight Diagnostics, Inc.
Aug 29, 2025, 16:05 ET Ginkgo Bioworks Issues Notice of Settlement of Shareholder Derivative Actions
BOSTON, Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice:
More news about: Ginkgo Bioworks
Aug 29, 2025, 07:30 ET YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market
Aug. 29, 2025 /PRNewswire/ -- YD Bio Limited ("YD Bio Ltd" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of its previously announced business
More news about: YD Bio Limited
Aug 29, 2025, 00:00 ET Cognizant to Deploy 1,000 Context Engineers, Powered by ContextFabric™, to Industrialize Agentic AI
for enterprise AI. Cognizant's 1,000 context engineers will be powered by Workfabric AI's ContextFabric™ platform, which transforms the organizational DNA of enterprises — how their teams work, including their workflows, data, rules, and processes — into actionable context for AI agents. By serving as a
More news about: Cognizant
Aug 29, 2025, 00:00 ET Cognizant to Deploy 1,000 Context Engineers, Powered by ContextFabric™, to Industrialize Agentic AI
for enterprise AI. Cognizant's 1,000 context engineers will be powered by Workfabric AI's ContextFabric™ platform, which transforms the organizational DNA of enterprises — how their teams work, including their workflows, data, rules, and processes — into actionable context for AI agents. By serving as a
More news about: Cognizant
Aug 28, 2025, 17:31 ET GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight
Actuate Therapeutics, is a selective small-molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β)—an enzyme involved in cell proliferation, DNA repair, and immune regulation. Inhibiting GSK-3β with 9-ING-41 can make tumors more responsive to chemotherapy, reduce fibrosis-related signaling, and
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 16:58 ET Dr. Douglas Farris Joins Hopkins Dermatology in Southlake, TX, Bringing Expertise in Functional Medicine, Hair Restoration, and General Dermatology
and female hair loss using advanced therapies like TrichoTest®, a genetic analysis that identifies the most effective treatments based on individual DNA. He combines this with exosome therapy, PRP injections, and laser photo bio-stimulation—all available at Hopkins Dermatology—for maximum results.
More news about: Hopkins Dermatology
Aug 28, 2025, 12:26 ET iMused.ai Launches as the First Ethical AI Music Platform Highlighting a New Era for Artists, Rights, and the Future of Creative Collaboration
Production and Promotions Company, today debuts the first ethical AI music platform designed to protect, credit, and pay artists every time their creative DNA inspires a new track, ushering in a game-changing model for AI-powered music creation and copyright compliance. iMused.ai launches amid industry
More news about: The 144k Collective
Aug 28, 2025, 10:00 ET Fresh Air for Back-to-School Season: Daikin Offering 30% Discount on Room Air Purifiers Through September 30, 2025
Technologies North America, Inc. (DNA) is a subsidiary of DIL, providing Daikin, Goodman, Amana® and Quietflex brand products. DNA and its affiliates manufacture heating and cooling systems for residential, commercial and industrial use that are sold via independent HVAC contractors. DNA engineering and manufacturing
More news about: Daikin
Aug 28, 2025, 10:00 ET Consumers for Dental Choice salutes new guidance from Florida: Stop placing mercury-based dental fillings
"Amalgam releases low levels of mercury in the form of a vapor, which can be inhaled and absorbed by the lungs and other organs, and has been found to cause DNA damage in human blood cells and potential impairment with renal [kidney] function." Even more alarming, he notes that dental mercury can be linked to
More news about: Consumers for Dental Choice
Aug 28, 2025, 08:34 ET Toyota RAV4 Wins 2026 Green Car of the Year! Cadillac, Fiat, Jeep, and Mitsubishi Also Earn Green Car Awards
YearWagoneer S, Jeep's first all-electric model, is an important addition to the brand, blending sleek styling along with signature Jeep DNA to encourage on- and off-pavement journeys. The mid-size SUV's Launch Edition and entry-level Limited trim feature a 294 mile range. Mitsubishi
More news about: Green Car Journal
Aug 28, 2025, 08:00 ET Relay Capital Group and MENA Growth Partners Announce Strategic Alliance to Build the Premier U.S. - MENA Technology Investment Bridge
based startups and funds gain a turnkey partner for fundraising and liquidity, and go-to-market execution in the region. "Relay's DNA is bringing institutional grade sophistication to a maturing secondary market: this means unearthing and packaging up world class deals for sophisticated
More news about: MENA Growth Partners; Relay Capital
Aug 28, 2025, 08:00 ET Relay Capital Group and MENA Growth Partners Announce Strategic Alliance to Build the Premier U.S. - MENA Technology Investment Bridge
while U.S. based startups and funds gain a turnkey partner for fundraising and liquidity, and go-to-market execution in the region. "Relay's DNA is bringing institutional grade sophistication to a maturing secondary market: this means unearthing and packaging up world class deals for sophisticated
More news about: MENA Growth Partners; Relay Capital
Aug 28, 2025, 07:36 ET HTX Commits to Fulfilling Global Corporate Responsibility: Building a Charity Chain to Deliver Love and Care
Embedding Long-Term Philanthropy into Our Brand DNA HTX regards charitable work as a core element of its global brand strategy. Each initiative embodies respect for local cultures and serves as
More news about: HTX
Aug 28, 2025, 07:29 ET HTX Commits to Fulfilling Global Corporate Responsibility: Building a Charity Chain to Deliver Love and Care
Embedding Long-Term Philanthropy into Our Brand DNA HTX regards charitable work as a core element of its global brand strategy. Each initiative embodies respect for local cultures and serves as
More news about: HTX
Aug 28, 2025, 05:06 ET Trattamento clinico di base editing ad alta precisione per l'anemia falciforme: CS-101 di CorrectSequence Therapeutics ottiene risultati promettenti sul primo paziente
convenzionali basate su CRISPR/Cas9, CS-101 garantisce un recupero emopoietico efficiente e un rapporto HbF-HbS maggiore, senza i rischi di grandi delezioni del DNA, riarrangiamenti cromosomici o mutazioni fuori bersaglio. A tutt'oggi, CS-101 è stata impiegata per trattare circa 20 pazienti affetti da β-talassemia
More news about: CorrectSequence Therapeutics
Aug 28, 2025, 04:49 ET Hochpräzise Basen-Editierung zur klinischen Behandlung der Sichelzellenkrankheit - CS-101 von CorrectSequence Therapeutics erzielt vielversprechende Ergebnisse bei erstem Patienten
CRISPR/Cas9-basierten Therapien sorgt CS-101 für eine effiziente hämatopoetische Erholung und ein höheres HbF-zu-HbS-Verhältnis, ohne das Risiko großer DNA-Deletionen, chromosomaler Umlagerungen oder Off-Target-Mutationen. Bis heute wurde CS-101 in klinischen Studien zur Behandlung von fast 20 Patienten
More news about: CorrectSequence Therapeutics
Aug 27, 2025, 14:51 ET Ao vencer o Paris DNA Design Award 2025, a bicicleta elétrica Santa Monica da AIMA impulsiona a evolução das e-bikes
PARIS, 27 de agosto de 2025 /PRNewswire/ -- Recentemente, foi anunciada a lista de vencedores do Paris DNA Design Awards 2025. A bicicleta elétrica Santa Monica, modelo de e-bike da AIMA TECHNOLOGY GROUP CO., LTD., uma das principais empresas de veículos elétricos
More news about: AIMA Technology
Aug 27, 2025, 11:48 ET Hemi, World's Largest Bitcoin Programmability Layer, Launches $HEMI Token on Binance
Crypto.com, DNA Fund, Selini Capital,
More news about: Hemi
Aug 27, 2025, 09:30 ET Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0
Aug. 27, 2025 /PRNewswire/ -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug
More news about: HitGen Inc.
Aug 27, 2025, 08:00 ET Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device - the first
More news about: Lucid Diagnostics